A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-679/ECHO-302
- Sponsors Incyte Corporation
- 25 Jul 2024 Results assessing comparison of pembrolizumab plus epacadostat with sunitinib or pazopanib as first-line treatment for mRCC presented in the BMC Cancer
- 15 May 2023 Planned End Date changed from 4 Feb 2023 to 31 Dec 2024.
- 01 Jul 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record